CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Share :
Published: 13 Jun 2019
Views: 2045
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Prof Heinz-Josef Lenz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated results from a study he presented at ESMO 2018.

The MSI high metastatic colon cancer patients report an improved efficacy, and at 15 months over 80% have not progressed with a low toxicity profile.


We have actually an updated result from an ESMO presentation in Munich where we presented data on 45 patients with MSI high metastatic colon cancer. The median follow-up in Munich was 9.9 months and we have now 20 months. We are very excited to report that the efficacy looks even better today. The response rate is now to 64% and we have not reached duration of response, not reached progression free survival and obviously not reached overall survival.

At 15 months over 80% have still not seen progression. This will translate into the most effective treatment of any subgroup for metastatic colon cancer. We are very excited because the toxicity profile remains extremely well tolerated, we have not seen any more additional adverse events.

So this treatment for MSI tumours which are known to be poorly prognostic doing extremely well with a well-tolerated immunotherapy without any impact of chemotherapy. So we are very excited, we hope this will be evaluated and potentially useable and FDA approved for first line treatment.